Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.55 |
| ▸ | CDK1 | P06493 | 5/20 | 0.55 |
| ▸ | ABL1 | P00519 | 5/20 | 0.55 |
| ▸ | PRKCA | P17252 | 2/20 | 0.55 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.48 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.43 |
| ▸ | ABL2 | P42684 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785011 | 0.90 | EGFR (0.54) | EGFRCDK1ABL1PRKCACAMK2D | |
| Hydrochloric Acid SCHEMBL5351366 | 0.89 | EGFR (0.53) | EGFRCDK1ABL1PRKCACAMK2D | |
| Hydrochloric Acid SCHEMBL5350968 | 0.89 | EGFR (0.53) | EGFRCDK1ABL1PRKCACAMK2D | |
| SCHEMBL5361357 | 0.87 | TTBK1 (0.48) | EGFRCDK1ABL1PRKCATTBK1 | |
| SCHEMBL5351369 | 0.83 | EGFR (0.59) | EGFRSRC | |
| SCHEMBL14355887 | 0.81 | NPC1 (0.46) | EGFRCDK1ABL1PRKCATP53 | |
| SCHEMBL5358394 | 0.80 | EGFR (0.56) | EGFRTTBK1TTBK2SRC | |
| SCHEMBL4742040 | 0.79 | EGFR (0.49) | EGFRCDK1ERBB2TTBK1TTBK2 | |
| SCHEMBL5362671 | 0.79 | RET (0.47) | EGFRTTBK1LMNA | |
| SCHEMBL5348597 | 0.76 | TTBK1 (0.49) | EGFRTTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | claimed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | claimed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | claimed |
| EP-1390371-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | Novartis AG (CH) | 2004-02-25 | — | — | EP | claimed |
| WO-2002092603-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | claimed |
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | disclosed |
| EP-1390371-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002092603-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | DPYD, COXFA4L2, MSH2 | EGFR 1321/4885CDK1 644/4885ABL1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.